Jason R. Manro

2.5k total citations
28 papers, 1.3k citations indexed

About

Jason R. Manro is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Jason R. Manro has authored 28 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 10 papers in Molecular Biology and 9 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Jason R. Manro's work include Cancer Immunotherapy and Biomarkers (5 papers), Advanced Breast Cancer Therapies (4 papers) and Cancer Mechanisms and Therapy (4 papers). Jason R. Manro is often cited by papers focused on Cancer Immunotherapy and Biomarkers (5 papers), Advanced Breast Cancer Therapies (4 papers) and Cancer Mechanisms and Therapy (4 papers). Jason R. Manro collaborates with scholars based in United States, Spain and Belgium. Jason R. Manro's co-authors include Ronald N. Hines, Sevasti B. Koukouritaki, Jeffrey Stevens, Chungang Gu, Peter J. Tandler, Matthew J. Zaya, Allan E. Rettie, D. Gail McCarver, Philip W. Iversen and Gerald E. Hall and has published in prestigious journals such as PLoS ONE, Cancer Research and Oncogene.

In The Last Decade

Jason R. Manro

28 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jason R. Manro United States	14	556	420	323	244	191	28	1.3k
Jamie L. Renbarger United States	20	806 1.4×	507 1.2×	311 1.0×	360 1.5×	159 0.8×	65	1.8k
Mayumi Saeki Japan	23	722 1.3×	730 1.7×	483 1.5×	413 1.7×	154 0.8×	58	1.7k
Ina Koch Germany	18	689 1.2×	505 1.2×	621 1.9×	150 0.6×	92 0.5×	33	1.6k
Anke Geick Germany	10	674 1.2×	407 1.0×	481 1.5×	253 1.0×	117 0.6×	11	1.3k
Poonkuzhali Balasubramanian India	26	553 1.0×	1.2k 2.9×	118 0.4×	208 0.9×	133 0.7×	137	2.4k
Alice A. Gibson United States	23	790 1.4×	391 0.9×	213 0.7×	261 1.1×	45 0.2×	46	1.4k
Javier G. Blanco United States	24	472 0.8×	600 1.4×	150 0.5×	420 1.7×	56 0.3×	75	1.8k
Jun-ichi Sawada Japan	20	751 1.4×	696 1.7×	243 0.8×	258 1.1×	52 0.3×	42	1.4k
Jiong Zhang China	17	226 0.4×	369 0.9×	320 1.0×	142 0.6×	83 0.4×	52	1.2k
Araba A. Adjei United States	19	377 0.7×	616 1.5×	209 0.6×	77 0.3×	96 0.5×	32	1.3k

Countries citing papers authored by Jason R. Manro

Since Specialization

Citations

This map shows the geographic impact of Jason R. Manro's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jason R. Manro with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jason R. Manro more than expected).

Fields of papers citing papers by Jason R. Manro

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jason R. Manro. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jason R. Manro. The network helps show where Jason R. Manro may publish in the future.

Co-authorship network of co-authors of Jason R. Manro

This figure shows the co-authorship network connecting the top 25 collaborators of Jason R. Manro. A scholar is included among the top collaborators of Jason R. Manro based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jason R. Manro. Jason R. Manro is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Mur, Cecilia, W K Shen, Carlos Marugán, et al.. (2023). 41P Preclinical characterization of imlunestrant, an oral brain-penetrant selective estrogen receptor degrader with activity in a brain metastasis (BM) model. ESMO Open. 8(1). 101265–101265. 1 indexed citations

Li, Yanxia, Nelusha Amaladas, Jason R. Manro, et al.. (2022). Treatment with a VEGFR-2 antibody results in intra-tumor immune modulation and enhances anti-tumor efficacy of PD-L1 blockade in syngeneic murine tumor models. PLoS ONE. 17(7). e0268244–e0268244. 11 indexed citations

Poussin, Mathilde, Arlene Sereno, Xiufeng Wu, et al.. (2021). Dichotomous impact of affinity on the function of T cell engaging bispecific antibodies. Journal for ImmunoTherapy of Cancer. 9(7). e002444–e002444. 21 indexed citations

Bhagwat, Shripad V., Baohui Zhao, Weihua Shen, et al.. (2021). Abstract 1236: Preclinical characterization of LY3484356, a novel, potent and orally bioavailable selective estrogen receptor degrader (SERD). Cancer Research. 81(13_Supplement). 1236–1236. 18 indexed citations

Fischl, Anthony S., Xiaoen Wang, Beverly L. Falcón, et al.. (2019). Inhibition of Sphingosine Phosphate Receptor 1 Signaling Enhances the Efficacy of VEGF Receptor Inhibition. Molecular Cancer Therapeutics. 18(4). 856–867. 16 indexed citations

Holmgaard, Rikke, David Schaer, Yanxia Li, et al.. (2018). Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade. Journal for ImmunoTherapy of Cancer. 6(1). 47–47. 267 indexed citations

Yan, S. Betty, Suzane L. Um, Victoria L. Peek, et al.. (2017). MET-targeting antibody (emibetuzumab) and kinase inhibitor (merestinib) as single agent or in combination in a cancer model bearing MET exon 14 skipping. Investigational New Drugs. 36(4). 536–544. 33 indexed citations

Chen, S-H, Robert D. Van Horn, Taiqi Yin, et al.. (2017). RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1. Oncogene. 37(6). 821–832. 58 indexed citations

Wu, Wenjuan, Shripad V. Bhagwat, Constance King, et al.. (2017). Abstract 317: Combination of a novel ERK1/2 inhibitor (LY3214996) with CDK4 and CDK6 inhibitor (abemaciclib) enhances antitumor efficacy in KRAS mutant non-small cell lung cancer (NSCLC). Cancer Research. 77(13_Supplement). 317–317. 1 indexed citations

10.

Dempsey, Jack, Lysiane Huber, Amélie Forest, et al.. (2017). Abstract 583: The CDK4/6 inhibitor abemaciclib induces synergistic immune activation and antitumor efficacy in combination with PD-L1 blockade. Cancer Research. 77(13_Supplement). 583–583. 2 indexed citations

11.

Atkinson, Jennifer M., Kenneth B. Rank, Yi Arial Zeng, et al.. (2015). Activating the Wnt/β-Catenin Pathway for the Treatment of Melanoma – Application of LY2090314, a Novel Selective Inhibitor of Glycogen Synthase Kinase-3. PLoS ONE. 10(4). e0125028–e0125028. 91 indexed citations

12.

Yan, S. Betty, Suzane L. Um, Victoria L. Peek, et al.. (2014). Abstract 4403: Preclinical evaluation of LY2801653, an orally bioavailable small molecule oncokinase inhibitor, in cholangiocarcinoma models. Cancer Research. 74(19_Supplement). 4403–4403. 1 indexed citations

13.

Wu, Wenjuan, Bi Chen, Kelly M. Credille, et al.. (2013). Inhibition of Tumor Growth and Metastasis in Non–Small Cell Lung Cancer by LY2801653, an Inhibitor of Several Oncokinases, Including MET. Clinical Cancer Research. 19(20). 5699–5710. 53 indexed citations

14.

Bender, Mark H., Hong Gao, Andrew Capen, et al.. (2013). Abstract 1131: Novel inhibitor of Notch signaling for the treatment of cancer.. Cancer Research. 73(8_Supplement). 1131–1131. 13 indexed citations

15.

Higgins, J. William, Jing Bao, Alice Ke, et al.. (2013). Utility of Oatp1a/1b-Knockout and OATP1B1/3-Humanized Mice in the Study of OATP-Mediated Pharmacokinetics and Tissue Distribution: Case Studies with Pravastatin, Atorvastatin, Simvastatin, and Carboxydichlorofluorescein. Drug Metabolism and Disposition. 42(1). 182–192. 75 indexed citations

16.

Haas, Joseph V., Jason R. Manro, Harlan E. Shannon, et al.. (2012). In Vivo Assay Guidelines. Europe PMC (PubMed Central). 1 indexed citations

17.

Zeng, Wei, Lei Yan, Victoria L. Peek, et al.. (2012). Abstract 2734: c-Met antibody LY2875358 (LA480) shows differential antitumor effects in non-small cell lung cancer. Cancer Research. 72(8_Supplement). 2734–2734. 5 indexed citations

18.

Ryder, John, Julie F. Falcone, Jason R. Manro, Kjell Svensson, & Kalpana Merchant. (2006). Pharmacological Characterization of cGMP Regulation by the Biarylpropylsulfonamide Class of Positive, Allosteric Modulators of α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid Receptors. Journal of Pharmacology and Experimental Therapeutics. 319(1). 293–298. 11 indexed citations

19.

Koukouritaki, Sevasti B., Jason R. Manro, Jeffrey Stevens, et al.. (2004). Developmental Expression of Human Hepatic CYP2C9 and CYP2C19. Journal of Pharmacology and Experimental Therapeutics. 308(3). 965–974. 236 indexed citations

20.

Stevens, Jeffrey, Ronald N. Hines, Chungang Gu, et al.. (2003). Developmental Expression of the Major Human Hepatic CYP3A Enzymes. Journal of Pharmacology and Experimental Therapeutics. 307(2). 573–582. 289 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact